These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Production and Immunological Evaluation of Epitope-based Preventative Pneumococcal Candidate Vaccine Comprising Immunodominant Epitopes from PspA, CbpA, PhtD and PiuA Antigens. Dorosti H; Nezafat N; Heidari R; Ghoshoon MB; Gholami A; Dehshahri A; Erfani N; Rahbar MR; Ghasemi Y Curr Pharm Biotechnol; 2021 Oct; 22(14):1900-1909. PubMed ID: 33390108 [TBL] [Abstract][Full Text] [Related]
4. A new candidate epitope-based vaccine against PspA PhtD of Shafaghi M; Bahadori Z; Barzi SM; Afshari E; Madanchi H; Mousavi SF; Shabani AA Front Cell Infect Microbiol; 2023; 13():1271143. PubMed ID: 38035337 [TBL] [Abstract][Full Text] [Related]
5. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. Singh R; Singh S; Sharma PK; Singh UP; Briles DE; Hollingshead SK; Lillard JW PLoS One; 2010 Feb; 5(2):e9432. PubMed ID: 20195541 [TBL] [Abstract][Full Text] [Related]
6. Immunoinformatics-aided design of a new multi-epitope vaccine adjuvanted with domain 4 of pneumolysin against Streptococcus pneumoniae strains. Shafaghi M; Bahadori Z; Madanchi H; Ranjbar MM; Shabani AA; Mousavi SF BMC Bioinformatics; 2023 Feb; 24(1):67. PubMed ID: 36829109 [TBL] [Abstract][Full Text] [Related]
7. The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1. Cornick JE; Tastan Bishop Ö; Yalcin F; Kiran AM; Kumwenda B; Chaguza C; Govindpershad S; Ousmane S; Senghore M; du Plessis M; Pluschke G; Ebruke C; McGee L; Sigaùque B; Collard JM; Bentley SD; Kadioglu A; Antonio M; von Gottberg A; French N; Klugman KP; Heyderman RS; Alderson M; Everett DB; Vaccine; 2017 Feb; 35(6):972-980. PubMed ID: 28081968 [TBL] [Abstract][Full Text] [Related]
8. Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection. Chen A; Mann B; Gao G; Heath R; King J; Maissoneuve J; Alderson M; Tate A; Hollingshead SK; Tweten RK; Briles DE; Tuomanen EI; Paton JC Clin Vaccine Immunol; 2015 Oct; 22(10):1079-89. PubMed ID: 26245351 [TBL] [Abstract][Full Text] [Related]
9. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies. da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805 [TBL] [Abstract][Full Text] [Related]
10. In-silico design and evaluation of an epitope-based serotype-independent promising vaccine candidate for highly cross-reactive regions of pneumococcal surface protein A. Afshari E; Cohan RA; Sotoodehnejadnematalahi F; Mousavi SF J Transl Med; 2023 Jan; 21(1):13. PubMed ID: 36627666 [TBL] [Abstract][Full Text] [Related]
11. Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity. Wagner-Muñiz DA; Haughney SL; Kelly SM; Wannemuehler MJ; Narasimhan B Front Immunol; 2018; 9():325. PubMed ID: 29599766 [No Abstract] [Full Text] [Related]
12. Intranasal Immunization with the Commensal Shekhar S; Khan R; Schenck K; Petersen FC Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742 [No Abstract] [Full Text] [Related]
13. Immunoinformatics Prediction and Protective Efficacy of Vaccine Candidate PiuA-PlyD4 Against Streptococcus Pneumoniae. Miao C; Cui Y; Li Y; Qi Q; Shang W; Chen H; Gao Y; Yuan R; Long Q; Wu W; Wang X; Yan Z; Jiang Y Drug Des Devel Ther; 2023; 17():3783-3801. PubMed ID: 38146490 [TBL] [Abstract][Full Text] [Related]
14. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments. Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747 [TBL] [Abstract][Full Text] [Related]
15. Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection. Khan MN; Xu Q; Pichichero ME Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895132 [TBL] [Abstract][Full Text] [Related]
16. In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant. Bahadori Z; Shafaghi M; Madanchi H; Ranjbar MM; Shabani AA; Mousavi SF J Transl Med; 2022 Sep; 20(1):389. PubMed ID: 36059030 [TBL] [Abstract][Full Text] [Related]
17. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains. Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745 [TBL] [Abstract][Full Text] [Related]
18. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice. Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026 [TBL] [Abstract][Full Text] [Related]